In general, a single HCM-heterozygous mutation is sufficient to affect myocardialfunction and lead to hypertrophy; however, early studies have associated variants inthe MYBPC3 gene with incomplete penetrance, mild VH, low SCD riskand benign clinical evolution23-25. Here, MYBPC3 is linked to cardiac hypertrophy.